Abstract 2533
Background
ICIs are pivotal therapies in the treatment of pts with R/M HNSCC. The dismal OS of some pts underscores the need to detect pre-treatment prognostic scores.
Methods
Pts with R/M HNSCC receiving pembrolizumab (P) or nivolumab (N) were included in this retrospective analysis. We analyzed the impact of the following pre-treatment variables for OS using a Cox proportional hazards regression model: drug type, age, sex, tumor site, line of therapy, p-16, albumin (alb), hemoglobin (Hb), lactic dehydrogenase (LDH), lymphocyte count (LC), platelets (PLT), and neutrophil counts (NC).
Results
66 pts (55%) treated with N and 55 (45%) with P were included. Characteristics: Sex: Male 100 pts (83%), female 21 pts (17%); Mean Age: 62 (SD 11); Performance Status 0-1: 63 pts (52%), 2-3: 58 pts (48%); Line of therapy, 1: 43 pts (36%), 2: 58 pts (48%), 3-4: 20 pts (16%); P-16: positive 44 pts (36%), negative 77 pts (64%); Tumor site: oropharynx 54 pts (45%), oral cavity 23 pts (19%), larynx 16 pts (13%), other 28 pts (23%); Response: complete 11 pts (9%), partial 3 pts (2%), stable disease 47 pts (39%); and disease progression: 60 pts (50%). The OS at 1 and 2 years were 52% (95% confidence interval (CI), 43%-62%) and 27% (CI 17%-42%), respectively. Age, sex, PLT, NC, LC, p-16, alb, Hb, and LDH were included in the multivariable Cox model. Adjusted hazard ratio estimates are: P-16: 0.53 (CI 0.3-0.95, P = 0.03); LC: 0.67 (CI 0.46-0.97, P = 0.03); NC: 1.25 (CI 1.01-1.56, P = 0.04); LDH: 1.67 (CI 1.01-2.78, P = 0.04); Hb: 1.69 (CI 1.00-2.87, P = 0.05); alb: 1.69 (CI 0.94-3.02, P = 0.08); PLT: 1.06 (CI 0.82, 1.37, P = 0.7); Age: 1.02 (CI 0.78-1.34, P = 0.9); and Sex: 0.98 (CI 0.5-1.91, P = 0.9). This model was used to create a nomogram based prognostic score for 1 and 2 year OS probability and median OS time. Internal model validation using bootstrapped based bias corrected estimates showed Nagelkerke’s R2 = 0.18, calibration slope of 0.67, and C-index of 0.7.
Conclusions
Pre-treatment LC, NC as well as LDH, Hb, alb, and p-16 had the largest impact on OS based on a prognostic nomogram. The nomogram may help treatment decisions regarding ICI use in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract